Skip to content
Search

Latest Stories

NPA: Hub and spoke impact assessment proves justification for pharmacy cut was hollow

The National Pharmacy Association (NPA) has called for an immediate reconsideration on pharmacy funding as the official impact assessment of hub and spoke dispensing reveals that only limited extent of savings may be possible under the model.

The total savings to the pharmacy sector’s operational costs are calculated to be approximately £1 million by 2024, when the current contractual framework comes to an end. This compares to well over a billion pounds withheld from the sector over the contract period (2019-24), due to flat funding below inflation.


The NPA claims that the real-terms funding cuts since 2019, and indeed earlier cuts, were based in part on government promises of cost savings through hub and spoke.

Nick Kaye, NPA vice-chair, said:“The current 5-year funding deal promised clinical service developments, but with a downward ratchet on funding predicated on dispensing efficiencies. The promise was that independents would have the same opportunity as large multiples to secure the benefits of outsourcing elements of dispensing to a hub. Now it is clear that hundreds of independents won’t be in a position to benefit at all and that the savings for others will be miniscule compared to the money taken out of the global sum.

“These official figures confirm that there is an enormous gap between money taken out and any potential savings from hub and spoke.

Kaye called for an "honest conversation about efficiencies - a conversation that reflects the reality for independents struggling to survive."

“The government should go back to the drawing board on pharmacy funding, now that one of the central arguments for cuts has been exposed as completely hollow,” he added.

According to NPA calculation, had the global sum increased in line with inflation (including future projections) throughout the five years of the deal to 2024, more than £1.2bn in funding would have flowed to community pharmacy by 2024.

The Department of Health and Social Care impact assessment accompanied the launch of a consultation on legislative changes needed to permit hub and spoke between different legal entities. The consultation ends on 8 June.

More For You

Kelso Pharma continues expansion with £140M funding boost

Kelso Pharma will use the funds to support further acquisitions and expand in the UK and Europe.

Getty Images

Kelso Pharma secures over £140m of acquisition funding

Kelso Pharma has secured more than £140 million of acquisition funding to support its expansion in the UK and across Europe.

The specialty pharmaceuticals business today (27) confirmed that a proportion of the funding was used for its acquisition of ALTURiX last month, a deal that doubled the size of the company’s UK business.

Keep ReadingShow less
Community pharmacist accessing GP Connect Access Record on Cegedim Rx platform

GP Connect Access Record will make a patient’s relevant medical information available to pharmacy.

Getty Images

Cegedim Rx activates GP Connect Access Record

Community pharmacy IT supplier Cegedim Rx has made GP Connect Access Record functionality available across its clinical services platform, providing registered pharmacy professionals with enhanced access to patient medical information.

The new feature, now live on Cegedim Rx’s Pharmacy Services platform, allows community pharmacies to retrieve relevant medical data when delivering NHS clinical services.

Keep ReadingShow less
Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

Patients who purchase two prescriptions per month could save more than £110 annually with a 12-month PPC.

Getty Images

Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

The NHS Business Services Authority (NHSBSA) has published a new experimental analysis, estimating patient savings achieved from prescription prepayment certificates (PPCs), including Hormone Replacement Therapy (HRT) PPCs.

The report revealed that the number of Prescription Prepayment Certificates (PPCs) purchased has risen consistently over the past five years, with 3.3 million patients receiving NHS prescriptions under a PPC exemption in 2023/2024.

Keep ReadingShow less
Three pharmacists named in NIHR’s latest cohort of senior investigators

L-R: Professor David Alldred; Professor Rachel Elliott and Professor Ian Maidment.

Three pharmacists appointed as NIHR senior investigators

The National Institute for Health and Care Research (NIHR) has announced its latest cohort of senior investigators, including three distinguished pharmacists.

David Alldred, professor of medicines use and safety at the University of Leeds; Rachel Elliott, professor of health economics at the University of Manchester; and Ian Maidment, professor in clinical pharmacy at Aston University, have been named in the list of 39 new appointments, alongside 19 reappointed senior investigators.

Keep ReadingShow less
Vaccine-preventable infections costing UK billions

Effective interventions are needed to prevent hospitalisations

Vaccine-preventable infections costing UK billions

Effective interventions are having a positive impact but more needs to be done to combat vaccine-preventable infections after data revealed today showed that it accounted for 20 per cent of hospital bed usage in the UK between 2023 to 2024 at a cost of almost £6 billion.

The return of social mixing, international travel and migration following the COVID-19 pandemic have contributed to the rise in both endemic disease and vaccine-preventable infections, according to the UK Health Security Agency's (UKHSA).

Keep ReadingShow less